Deer IX & Co. Ltd.
CIK
1655220
Location
Larchmont, NY
Portfolio Value
Micro
$46,565,183
Diversification
Highly concentrated
Filing Date
Global Rank
#5,031
/ 5,929
▼ 160
· as of Sep 2021
Top Industry
Biotechnology
100.0%
3Y Alpha vs SPY
+40.8%
Period ended 4 years ago
Filed Nov 15, 2021 · 4y
4 quarters · since Dec 2020
Clone Performance
Jul 2023–Jul 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+322.5%
SPY
+76.0%
Annualised alpha
+40.9%
Max drawdown
−65.0%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
2 positions · as of Sep 30, 2021 · Δ vs Jun 30, 2021Top Position
77.7%
−22.3 pts
Top 5
100.0%
0.0 pts
Top 10
100.0%
0.0 pts
HHI
6,534
Highly concentrated−3,466
Portfolio Trend
4 quarters · across all stocks
Sector Breakdown
As of Sep 30, 2021| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $46,565,183 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedNo qualifying positions this quarter.
Trimmed
Positions the filer reduced
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | −619,413 | 615,895 | $36,177,672 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| TCRX | TScan Therapeutics, Inc. | 1,245,505 | $10,387,511 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exitedNo qualifying positions this quarter.
2 positions ·
$46,565,183 total
· as of Sep 30, 2021
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Reduced | 615,895 | $36,177,672 | 77.69% | |
| TCRX |
TScan Therapeutics, Inc.
Healthcare
|
NEW | 1,245,505 | $10,387,511 | 22.31% |